Healthcare / Medical Instruments & SuppliesBSE
$18.41
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $36.4M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$266M
P/E
20.9x
↑EV/EBITDA
11.3x
↓ROE
3.3%
↑Gross Margin
16.2%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
-12.0%
FCF CAGR
-5.4%
FCF margin
8.7%
FCF / Net income
3.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $561.0M · net income $12.6M · FCF $48.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $561.0M | $561.0M | $837.1M | $797.5M | $823.1M |
| Net Income | $12.6M | $12.6M | $20.7M | $20.1M | $20.7M |
| EBITDA | $28.7M | $28.7M | $46.3M | $51.1M | $53.9M |
| EPS | — | — | 1.43 | 1.39 | 1.44 |
| Gross Margin | 16.2% | 16.2% | 11.1% | 12.5% | 15.6% |
| Operating Margin | 4.2% | 4.2% | 4.6% | 5.7% | 5.7% |
| Net Margin | 2.3% | 2.3% | 2.5% | 2.5% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.34 | 0.40 | 0.50 |
| Current Ratio | 4.52 | 4.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $48.9M | $48.9M | $36.4M | $34.1M | $57.7M |
| Returns | |||||
| ROE | 3.3% | 3.3% | 5.6% | 5.8% | 6.3% |
| Valuation | |||||
| P/E | 20.92 | 20.92 | 11.19 | 22.30 | 11.81 |
| EV/EBITDA | 11.34 | 11.34 | 7.08 | 11.26 | 7.25 |
| P/B | 0.69 | 0.69 | 0.63 | 1.28 | 0.75 |
| Growth & Yield | |||||
| Revenue Growth | -33.0% | -33.0% | 5.0% | -3.1% | — |
| EPS Growth | — | — | 2.9% | -3.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.2%
Start / end P/E
n/dx → n/dx
EPS bridge
1.43 → n/d
Residual
+1.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.